The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
Latest Information Update: 28 May 2024
At a glance
- Drugs NC-318 (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 23 May 2024 Planned End Date changed from 1 Jun 2025 to 30 Jun 2025.
- 23 May 2024 Planned primary completion date changed from 1 Jun 2025 to 30 Jun 2025.
- 04 Mar 2024 Planned number of patients changed from 141 to 159.